Sign in Subscribe
Drugs

Gemin X Biotechnologies' GX15-070 Exhibits Promising Results in Preclinical Studies Against Blood Cancers

Strategic Insights

— 2 min read

Gemin X Biotechnologies, Inc.'s GX15-070, a first-in-class targeted cancer treatment, has shown significant promise in preclinical studies against multiple types of blood cancers, including mantle cell lymphoma, multiple myeloma, acute myeloid leukemia, and chronic lymphocytic leukemia. The data, presented at the American Society of Hematology's 47th Annual Meeting and Exposition in Atlanta, Georgia, demonstrate that GX15-070 induces apoptosis in cancer cells and exhibits a synergistic effect when combined with other cancer drugs. These findings suggest that GX15-070 may be a valuable addition to the treatment arsenal for patients with these aggressive blood cancers.

Key Takeaways:

  • GX15-070 induced apoptosis in mantle cell lymphoma (MCL) cell lines and primary cells in vitro, both as a single agent and in combination with the bortezomib (Velcade) proteasome inhibitor.
  • The combination of GX15-070 with bortezomib resulted in a synergistic effect, allowing a 5-20X reduction in the dose of bortezomib required to kill cancer cells.
  • GX15-070 induced apoptosis in all 12 human myeloma cell lines tested and in the first and only primary myeloma sample tested, with no cytotoxicity to normal human blood lymphocytes, stroma, or bone marrow cells.
  • The compound induced apoptosis in approximately 64% of acute myeloid leukemia (AML) cells within 72 hours and in 85% of primary AML samples within 24 hours.
  • GX15-070 demonstrated the ability to induce apoptosis in samples from leukemia patients carrying the t(4;11) mutation, which often causes resistance to standard chemotherapy.
  • The combination of GX15-070 with several chemotherapeutic agents suggested the ability to achieve cytotoxicity with lower doses of the chemotherapeutics.

Statistics:

  • 64% of AML cells induced apoptosis within 72 hours after treatment with GX15-070.
  • 85% of primary AML samples induced apoptosis within 24 hours after treatment with GX15-070.
  • 5-20X reduction in the dose of bortezomib required to kill cancer cells when combined with GX15-070.
  • All 12 human myeloma cell lines tested induced apoptosis after treatment with GX15-070.

Sources:

  • "The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib" (Patricia Perez-Galan, et al)
  • "Studies of the Bcl Inhibitor GX15-070 in Multiple Myeloma Demonstrate Substantial Preclinical Activity" (A. Keith Stewart, et al)
  • "Inhibition of Bcl-2 Signaling by Small Molecule BH3 Inhibitor GX15-070 as a Novel Therapeutic Strategy in AML" (Rooha Contractor, et al)
  • "Pan-BCL-2 Family Small Molecule Inhibitor GX15-070 (Gemin X, Inc.) Exhibits Single Agent Cytotoxicity, is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations" (Jessicca M Rege, PhD, et al)

Read more